Search results
Results from the WOW.Com Content Network
Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients ...
(Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older ...
KarXT is expected to drive sales through late-2020s and into the next decade, at a time when two of Bristol Myers' top drugs, blood cancer treatment Revlimid and blood thinner Eliquis face generic ...
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. [3] Lumateperone was approved for medical use in the United States in December 2019 with an initial indication for schizophrenia, [4] [5] and became available in February 2020. [2]
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey , [ 2 ] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
The lack of a warning sent Bristol Myers' shares up 6.3% at $53.28 in premarket trading on Friday. Bristol Myers obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of ...
Bristol Myers Squibb (NYSE: BMY) Q3 2024 Earnings Call Oct 31, 2024, 8:00 a.m. ET. Contents: ... formerly known as KarXT with a strong label that reflects its efficacy and safety profile. This ...